Blog
RSS FeedPosted by Michael Wonder on 10 Oct 2022
Federal drug price watchdog consulting public on proposed changes to its pricing guidelines
7 October 2022 - The PMPRB's guidelines explain how its staff monitor and review patented medicine prices to ensure they are ...
Posted by Michael Wonder on 10 Oct 2022
Mental health funding of £1.8 million welcomed by NICE and MHRA to explore regulation of digital mental health tools
10 October 2022 - NICE and the MHRA have been awarded £1.8 million funding by Wellcome over three years to explore ...
Posted by Michael Wonder on 04 Oct 2022
2022 October price disclosure cycle – confirmed prices and patient savings reports
1 October 2022 - Combination flow-on reduction outcomes reflect confirmed 1 October 2022 prices on the Current Price Disclosure cycle web ...
Posted by Michael Wonder on 31 Jul 2022
2022 October price disclosure cycle – patient savings
29 July 2022 - Indicative brand price reductions and patient savings resulting from the 2022 October Cycle of Price Disclosure have ...
Posted by Michael Wonder on 23 Jul 2022
European Union regulation of health technology assessment: what is required for it to succeed?
22 July 2022 - After considerable discussion and debate, the European Commission proposal for the regulation of health technology assessment was ...
Posted by Michael Wonder on 04 Jul 2022
2022 October price disclosure cycle – indicative prices
4 July 2022 - Indicative 1 October 2022 prices resulting from the 2022 October Cycle of Price Disclosure have now been ...
Posted by Michael Wonder on 26 Jun 2022
Price disclosure 2022 October cycle outcomes summary
24 June 2022 - The summary of price disclosure price reductions for the 2022 October Cycle has now been published on ...
Posted by Michael Wonder on 19 Jun 2022
Canadian drug prices: new regulations could save billions of dollars
15 June 2022 - New drug price regulations set to come into effect next month could lower spending on patented ...
Posted by Michael Wonder on 09 Jun 2022
The days of the independent republic of PHARMAC are far from over
9 June 2022 - When he announced the government’s response to the recent independent review of PHARMAC Health Minister Andrew Little ...
Posted by Michael Wonder on 08 Jun 2022
Updated price disclosure guidelines, price disclosure webpages and price disclosure dispute resolution process
8 June 2022 - Amendments made to the National Health Act 1953 and National Health (Pharmaceutical Benefits) Regulations 2017 by the ...
Posted by Michael Wonder on 25 May 2022
Remake of National Health (Supply of Pharmaceutical Benefits – Under Co-payment Data and Claims for Payment) Rules 2022
25 May 2022 - The Department has recently remade the National Health (Claims and under co-payment data) Rules 2012, now ...
Posted by Michael Wonder on 12 May 2022
After a 5 year fight to lower drug prices, Ottawa's pledge quietly falls apart
12 May 2022 - What began with a promise to protect Canadians ended with a commitment to support pharmaceutical companies. ...
Posted by Michael Wonder on 11 May 2022
Remake of the National Health (Pharmaceuticals and Vaccines – Cost Recovery) Regulations 2009
11 May 2022 - The Department has recently remade the National Health (Pharmaceutical and Vaccines—Cost Recovery) Regulations 2009 (2009 Regulations), ...
Posted by Michael Wonder on 23 Apr 2022
Canada is settling for half measures on drug price regulations
22 April 2022 - After a two-year delay, new federal regulations for patented medicine prices will come into force this ...
Posted by Michael Wonder on 12 Apr 2022
Prospective measures to combat rising drug prices in Germany
13 April 2022 - This article provides an overview of potential tools being explored in Germany by Health Insurance Funds to ...